Current Report Filing (8-k)
March 27 2017 - 08:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 27, 2017
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-33038
|
|
84-1475642
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
One First Avenue, Parris Building 34, Navy Yard Plaza
Boston, Massachusetts
|
|
02129
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(617)
259-1970
(Registrants telephone number, including area code)
Not applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the
Form 8-K
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR 240.14a-12).
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b)).
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c)).
|
Item 7.01
|
Regulation FD Disclosure
|
On March 27, 2017, ZIOPHARM Oncology, Inc., or the Company, issued a
press release announcing the receipt of positive guidance from an
End-of-Phase
2 meeting with the U.S. Food and Drug Administration (FDA) for its lead gene therapy
product candidate,
Ad-RTS-hIL-12
plus orally administered veledimex (V), to harness and control
IL-12
production for the investigational treatment of recurrent glioblastoma (GBM), an aggressive form of brain cancer with few treatment options.
The information contained in the press release furnished as Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of the Companys filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.
Item 9.01
|
Financial
Statements
and
Exhibits
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated March 27, 2017
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
ZIOPHARM Oncology, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Kevin G. Lafond
|
Date: March 27, 2017
|
|
|
|
|
|
Name:
|
|
Kevin G. Lafond
|
|
|
|
|
|
|
Title:
|
|
Senior Vice President, Chief Accounting Officer and Treasurer
|
3
INDEX OF EXHIBITS
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated March 27, 2017
|
4
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Feb 2024 to Mar 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Mar 2023 to Mar 2024